Opaganib, also known as ABC294640, is a selective sphingosine kinase-2 (SK2) (https://go.drugbank.com/polypeptides/Q9NRA0) inhibitor that is orally administered. This drug has potential anticancer, anti-inflammatory, and antiviral activities, with potential applications in...
- Mechanism
- Curator reviewed · 2 references
Opaganib selectively inhibits sphingosine kinase-2 (SK2) (https://go.drugbank.com/polypeptides/Q9NRA0). This inhibition blocks the synthesis of sphingosine 1-phosphate (S1P) and its activities (which includes regulation of fundamental biological processes such as cell proliferation, migration, immune cell trafficking, angiogenesis, immune-modulation, and suppression of innate immune responses from T-cells). This drug has dual anti-inflammatory and antiviral activity targeting a host cell component and is unaffected by viral mutation, contributing to minimization of the likelihood of resistance. It is currently being investigated against COVID-19 as it has demonstrated anti-SARS-CoV-2 activity in studies.
- Formula / weight
- C23H25ClN2O · 380.92 g/mol (avg)
- Also known as
- 4-Pyridinylmethyl 3(4-Chlorophenyl)Adamantine Carboxamide · 4-Pyridinylmethyl-3-(4-Chlorophenyl) Adamantine Carboxamide · Yeliva
- Code names
- ABC294640
Resolves to
CAOTVXGYTWCKQE-UHFFFAOYSA-NSMILESClC1=CC=C(C=C1)C12CC3CC(CC(C3)(C1)C(=O)NCC1=CC=NC=C1)C2What you can answer from here — as of April 23, 2025
Which drugs share a target with Opaganib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account